Takeda Pharmaceutical revenue and financials
¥5,766.00Change from previous close: +0.82%Absolute change: +¥47.00
In the fiscal year ended March 2026, Takeda Pharmaceutical reported revenue of ¥4.51T (−1.66% year over year). The net loss was ¥152.39B.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −1.66%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- -3.4%
- FY to Mar 2025: 2.4%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 128 | 74,528 | 373,252 | 378,228 | 215 | — |
| Depreciation and amortization | — | 163,870 | 190,639 | 184,982 | 181,636 | 189,769 |
| Capital expenditure | — | -64,393 | -222,373 | -52,825 | -75,068 | -92,724 |
| Investing cash flow | -87.7 | -58,017 | -229,798 | -48,133 | -33.2 | — |
| Financing cash flow | -180 | -77,492 | -192,447 | -11,981 | -215 | — |
| Dividends paid | — | -8,787 | -149,032 | -8,787 | -145,295 | -9,738 |
| Share repurchases | — | 0.0 | 0.0 | 0.0 | -51,603 | -49,978 |
| Debt issued | — | 60,000 | 0.0 | 342,505 | 183,555 | 27,490 |
| Debt repaid | — | -427,395 | -9,886 | 35,830 | -183,533 | -547,992 |
| Effect of exchange rates | 6.4 | 1,099 | 22,444 | 13,364 | -2.4 | — |
| Net change in cash | -141 | -60,982 | -48,993 | 318,114 | -32.7 | — |
| Free cash flow | 128 | 10,135 | 150,879 | 325,403 | 215 | — |